Drug Trial Radar · NCT06908642
Evaluation the Safety of hemay005 Tablets
Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
468
Actual
Start
Dec 25, 2024
Primary completion
Jun 3, 2025
Study completion Jun 3, 2025
Sponsor
- Lead sponsor
- Anhui Hemay Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Hemay005 tabletDrug
Hemay005 is a small molecule PDE4 inhibitor.
PlaceboDrug
Placebos are the same as drugs, but contain no Hemay005.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.Time frame: 14 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.